MedBlog

How theragnostics seeks, finds, and destroys metastatic cancer

Theragnostics, an advanced combination of diagnostic and targeted therapy technology, uses radiopharmaceuticals to seek, find, and eliminate metastatic cancer cells while sparing healthy tissue. It is now available at UT Southwestern for pancreatic, thyroid, and several other cancers.

Orhan K. Oz, M.D., Ph.D.

May 1, 2023

TULSA treats prostate cancer with no incisions, surgery, or radiation

Men with localized, low- and intermediate-risk prostate cancer are seeking TULSA: an outpatient, alternative to surgery or active surveillance: no incisions, surgery, or radiation required. Learn more.

Yair Lotan, M.D. / Daniel Costa, M.D. / Kenneth Goldberg, M.D.

June 17, 2021

IORT: Treating cancer with internal radiation therapy

With brachytherapy, tiny implements deliver radiation directly to a tumor. And the list of cancers for which it is effective is expanding. Learn more about how UT Southwestern is leading the way in brachytherapy in Texas.

September 16, 2020

Genetic testing for prostate cancer: What men and their families should know

Prostate cancer can run in the family. Explore how genetic counseling can help families understand and potentially treat a range of genetic cancers.

Parker Read, M.S.

September 10, 2020

5 signs your back pain might be an emergency

Severe back pain might be a sign of a more serious underlying medical emergency. In this week’s MedBlog, two spine experts discuss five symptoms that should indicate seeing a doctor right away. Read more.

Douglas Dickson, M.D. / Kavita Trivedi, D.O.

July 3, 2019

What We Know About Your Prostate

Claus Roehrborn, M.D.

November 9, 2018

Sex after prostate cancer: Treatment choice matters

Men with prostate cancer and their partners often are reluctant to talk about sexual health after treatment, but it’s a natural concern. Learn about a treatment called SAbR that can preserve sexual potency and about a clinical trial that we hope will make it even safer.

Neil Desai, M.D.

June 18, 2018

Prostate cancer genomic testing is flawed: Three reasons why

Men with prostate cancer want to know the future: Will my cancer get worse? Do I need surgery? Genomic testing can help us make educated recommendations, but it’s far from perfect. Claus Roehrborn, M.D., explains why genomic testing isn’t a “crystal ball” for predicting prostate cancer risk.

Claus Roehrborn, M.D.

April 30, 2018

Prostate Cancer Awareness Guide

Prostate cancer is the second most common cancer in men. Use this guide to understand the risks, treatment options, and more.

June 14, 2017

Hormone therapy helps some prostate cancer survivors live longer

After prostate gland removal, cancer returns in up to 30% of men. But a 2017 study found that hormone-blockers plus radiation can prevent recurrence.

Claus Roehrborn, M.D. / Neil Desai, M.D.

February 8, 2017

Cancer Clinical Trials

Select cancer clinical trials that are open and seeking participants.

January 26, 2017

PSA tests: Can they save men from prostate cancer?

PSA blood tests are controversial in screening for prostate cancer. But Dr. Roehrborn says they save lives.

Claus Roehrborn, M.D.

October 11, 2016

UTSW teams exceed 1,000 targeted prostate biopsies

Dr. Claus Roehrborn and colleagues in Urology and Radiology are using a new, targeted biopsy method for prostate cancer that’s more effective than standard biopsies – and they’ve just reached a significant milestone.

Claus Roehrborn, M.D. / Ivan Pedrosa, M.D., Ph.D.

October 6, 2016